12:40 PM
 | 
Nov 14, 2018
 |  BC Extra  |  Politics & Policy

China NMPA expands on review timeline for new imported drug pathway

China’s National Medical Products Administration will decide whether to approve applications for certain imported drugs that have been approved in the U.S., EU or Japan within 10 business days after the agency's Drug Review Center completes its review.

The guidance applies...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >